2024-07-03 06:52:24 ET
Summary
- Eli Lilly’s new Alzheimer's drug, Kisunla, shows promise with its unique treatment regimen and potential competitive advantages over Biogen’s Leqembi.
- Despite challenges, Kisunla is priced aggressively at $32,000 per year, offering a potentially more cost-effective solution given its shorter treatment duration.
- Eli Lilly reported a 26% increase in revenue in Q1, driven by strong performances from its diabetes and obesity drugs.
- Eli Lilly is a buy due to its robust product portfolio and growth prospects, particularly from Zepbound.
Introduction
My last article on Eli Lilly ( LLY ) focused on their prospects in the multi-billion dollar obesity market with their GLP-1/GIP agonist, Zepbound (tirzepatide). On the heels of Zepbound, Eli Lilly's valuation, now $816 billion, has catapulted itself into the top 10 largest global market caps , trumping companies like Tesla ( TSLA ), Visa ( V ), and Walmart ( WMT ). Zepbound, approved in November 2023, brought in $517 million in Q1 and is projected to exceed $16 billion in sales per year by 2029. Moreover, Eli Lilly has a number of obesity-related assets, covering different mechanisms of action, in the pipeline, perhaps ensuring a " duopoly " with Novo Nordisk ( NVO ) in obesity treatment....
Read the full article on Seeking Alpha
For further details see:
Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval